Fundación Canaria de Investigación Sanitaria Report issue

Foundation Phase 2 Phase 3 Phase 4

Organization Overview

First Clinical Trial
2017
NCT03196388
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Fundación Canaria de Investigación Sanitaria

Active Ingredients

Drugs in Phase 4 Trials (3)

Anti-thymocyte Globulin (Rabbit) (Thymoglobulin) (1 trial)

mycophenolate (myfortic) (1 trial)

tacrolimus (prograf) (1 trial)

Drugs in Phase 3 Trials (2)

oxygen (1 trial)

ozone (1 trial)

Drugs in Phase 2 Trials (1)

enzalutamide (xtandi) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Coronary Artery Disease (Phase 3)

Heart Diseases (Phase 3)

Ischemia (Phase 3)

Myocardial Ischemia (Phase 3)

Prostatic Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 3
  • # of Trial APIs: 6